Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05635266 · ClinicalTrials.gov registry record
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
A clinical trial of Asthma and Alzheimer Disease, sponsored by Sanguine Biosciences.
- Recruiting
- Registry status
- 20,000
- Enrollment target
- 1
- Study location
NCT05635266 is a study of Asthma and Alzheimer Disease that is actively recruiting participants, run by Sanguine Biosciences. The registered enrollment target is 20,000 participants, above the 1,510-participant average among 374 other Asthma trials with a reported enrollment target (1225% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05635266, a study of Asthma and Alzheimer Disease, is actively recruiting participants, sponsored by Sanguine Biosciences.
- RECRUITING
- Registry status
- 20,000 participants
- Enrollment target
- 1
- Study location
Study Summary
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Specimen sample
Study Locations (1)
Massachusetts
- Sanguine Biosciences - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2021-10-26 |
| Est. Completion | 2025-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05635266
The ClinicalTrials.gov registry entry for NCT05635266 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,510-participant average among 374 other Asthma trials with a reported enrollment target (1225% higher). The listed sponsor is Sanguine Biosciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Specimen sample is the first listed.
NCT05635266 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05635266 about?
NCT05635266 is a clinical study titled "Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives". To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
What is the current status of trial NCT05635266?
This trial is currently recruiting. The enrollment target is 20,000 participants. The study started on 2021-10-26. Estimated completion is 2025-10.
What conditions does trial NCT05635266 study?
This clinical trial studies the following conditions: Asthma, Alzheimer Disease, Atopic Dermatitis, Age-related Macular Degeneration, Arthritis.
What interventions are being tested in trial NCT05635266?
The interventions under investigation include: Specimen sample (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05635266?
This trial is sponsored by Sanguine Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05635266 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.